Topgen

Topgen is a South Korean biotechnology company specializing in molecular diagnostics and the development of novel anti-cancer therapeutics. The company is widely recognized for its proprietary DNA chip technology, which powers a range of commercialized diagnostic kits for the detection of human papillomavirus (HPV), sexually transmitted diseases (STDs), and respiratory viruses. Beyond its diagnostic portfolio, Topgen is advancing a therapeutic pipeline focused on next-generation Topoisomerase I inhibitors, which are being developed as both standalone small molecule drugs and as payloads for antibody-drug conjugates (ADCs). The company's lead drug candidates, TG-101 and TG-102, are currently in pre-clinical development for the treatment of various solid tumors, including colorectal and ovarian cancers. Headquartered in Anyang, Topgen is listed on the KONEX market and continues to leverage its expertise in genomics to provide high-sensitivity precision medicine solutions.